← Human Trials & Peer-Reviewed Studies
The assessment of growth hormone status in normal young adult males using a variety of provocative agents.
Plain-language guide to PMID 8977752 (1996): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 subjects.
Key Facts
- PMID
- 8977752
- Journal
- Clinical endocrinology
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Rahim A et al. (3 authors)
- DOI
- 10.1046/j.1365-2265.1996.00855.x
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
In adults, there are few data regarding GH responses to provocative stimuli other than insulin-induced hypoglycaemia.
The researchers have compared the GH response to four different growth hormone secretagogues and placebo in normal healthy adult males.
Who Took Part
According to the abstract, 18 subjects were involved.
The age groups tagged for this paper are adults, men only.
This was a prospective, randomized, placebo-controlled study in 18 normal male subjects.
After an overnight last, an intravenous cannula was inserted into the arm of each subject and a blood sample was taken for GH at -30, -15, and 0 minutes.
How the Study Was Run
The design is described as randomized and placebo-controlled.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Some subjects received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
Further blood samples were taken at 15-minute intervals for 180 minutes for GH estimation.
What Was Measured
Topics PubMed links to this paper include Arginine, Clonidine, Glucagon, Growth Hormone and Insulin.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1996 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.